S&P 500   4,604.79 (+0.83%)
DOW   34,657.07 (+0.50%)
QQQ   395.28 (+0.37%)
AAPL   169.07 (+2.28%)
MSFT   335.38 (+1.45%)
FB   317.69 (-2.09%)
GOOGL   2,874.05 (+1.27%)
AMZN   3,501.86 (-0.15%)
TSLA   1,140.00 (-0.42%)
NVDA   323.05 (-1.14%)
BABA   124.86 (-2.09%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.32 (-2.56%)
GE   95.31 (+0.34%)
MU   87.40 (+4.05%)
T   22.59 (-1.05%)
F   20.00 (+4.22%)
DIS   144.89 (+-0.01%)
PFE   54.49 (+1.41%)
ACB   6.24 (-2.80%)
AMC   32.28 (-4.89%)
BA   193.79 (-2.05%)
S&P 500   4,604.79 (+0.83%)
DOW   34,657.07 (+0.50%)
QQQ   395.28 (+0.37%)
AAPL   169.07 (+2.28%)
MSFT   335.38 (+1.45%)
FB   317.69 (-2.09%)
GOOGL   2,874.05 (+1.27%)
AMZN   3,501.86 (-0.15%)
TSLA   1,140.00 (-0.42%)
NVDA   323.05 (-1.14%)
BABA   124.86 (-2.09%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.32 (-2.56%)
GE   95.31 (+0.34%)
MU   87.40 (+4.05%)
T   22.59 (-1.05%)
F   20.00 (+4.22%)
DIS   144.89 (+-0.01%)
PFE   54.49 (+1.41%)
ACB   6.24 (-2.80%)
AMC   32.28 (-4.89%)
BA   193.79 (-2.05%)
S&P 500   4,604.79 (+0.83%)
DOW   34,657.07 (+0.50%)
QQQ   395.28 (+0.37%)
AAPL   169.07 (+2.28%)
MSFT   335.38 (+1.45%)
FB   317.69 (-2.09%)
GOOGL   2,874.05 (+1.27%)
AMZN   3,501.86 (-0.15%)
TSLA   1,140.00 (-0.42%)
NVDA   323.05 (-1.14%)
BABA   124.86 (-2.09%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.32 (-2.56%)
GE   95.31 (+0.34%)
MU   87.40 (+4.05%)
T   22.59 (-1.05%)
F   20.00 (+4.22%)
DIS   144.89 (+-0.01%)
PFE   54.49 (+1.41%)
ACB   6.24 (-2.80%)
AMC   32.28 (-4.89%)
BA   193.79 (-2.05%)
S&P 500   4,604.79 (+0.83%)
DOW   34,657.07 (+0.50%)
QQQ   395.28 (+0.37%)
AAPL   169.07 (+2.28%)
MSFT   335.38 (+1.45%)
FB   317.69 (-2.09%)
GOOGL   2,874.05 (+1.27%)
AMZN   3,501.86 (-0.15%)
TSLA   1,140.00 (-0.42%)
NVDA   323.05 (-1.14%)
BABA   124.86 (-2.09%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.32 (-2.56%)
GE   95.31 (+0.34%)
MU   87.40 (+4.05%)
T   22.59 (-1.05%)
F   20.00 (+4.22%)
DIS   144.89 (+-0.01%)
PFE   54.49 (+1.41%)
ACB   6.24 (-2.80%)
AMC   32.28 (-4.89%)
BA   193.79 (-2.05%)
OTCMKTS:PMCB

PharmaCyte Biotech Stock Forecast, Price & News

$2.59
-0.03 (-1.15%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.50
$2.66
50-Day Range
$2.47
$3.39
52-Week Range
$2.25
$55.50
Volume
234,192 shs
Average Volume
1.99 million shs
Market Capitalization
$53.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.1
30 days | 90 days | 365 days | Advanced Chart
Receive PMCB News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.


PharmaCyte Biotech logo

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

Headlines

PharmaCyte Biotech (OTCMKTS:PMCB) Stock Price Up 4.8%
November 30, 2021 |  americanbankingnews.com
HC Wainwright Begins Coverage on PharmaCyte Biotech (OTCMKTS:PMCB)
November 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PMCB
Employees
4
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.00 per share

Profitability

Net Income
$-3.55 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$53.65 million
Optionable
Not Optionable

Company Calendar

Last Earnings
9/14/2021
Today
12/01/2021
Fiscal Year End
4/30/2022

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












PharmaCyte Biotech (OTCMKTS:PMCB) Frequently Asked Questions

Is PharmaCyte Biotech a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PharmaCyte Biotech in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PharmaCyte Biotech stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PMCB, but not buy additional shares or sell existing shares.
View analyst ratings for PharmaCyte Biotech
or view top-rated stocks.

How has PharmaCyte Biotech's stock been impacted by COVID-19 (Coronavirus)?

PharmaCyte Biotech's stock was trading at $0.0450 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PMCB shares have increased by 5,655.6% and is now trading at $2.59.
View which stocks have been most impacted by COVID-19
.

How were PharmaCyte Biotech's earnings last quarter?

PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) announced its quarterly earnings results on Tuesday, September, 14th. The company reported ($0.64) earnings per share for the quarter.
View PharmaCyte Biotech's earnings history
.

Who are PharmaCyte Biotech's key executives?

PharmaCyte Biotech's management team includes the following people:
  • Kenneth L. Waggoner, Chairman, President, CEO & Secretary
  • Carlos A. Trujillo, Chief Financial Officer & Director
  • José L. Iglesias, Chief Medical Officer
  • Gerald W. Crabtree, Director & Chief Scientific Officer
  • Lilli Brandtner, Director-Diabetes Program Development

What other stocks do shareholders of PharmaCyte Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PharmaCyte Biotech investors own include Co-Diagnostics (CODX), iBio (IBIO), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), OWC Pharmaceutical Research (OWCP), VBI Vaccines (VBIV) and Novavax (NVAX).

What is PharmaCyte Biotech's stock symbol?

PharmaCyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB."

Who are PharmaCyte Biotech's major shareholders?

PharmaCyte Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Schonfeld Strategic Advisors LLC (0.43%), Geode Capital Management LLC (0.23%) and NorthRock Partners LLC (0.18%).

Which major investors are buying PharmaCyte Biotech stock?

PMCB stock was acquired by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, Geode Capital Management LLC, and NorthRock Partners LLC.

How do I buy shares of PharmaCyte Biotech?

Shares of PMCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PharmaCyte Biotech's stock price today?

One share of PMCB stock can currently be purchased for approximately $2.59.

How much money does PharmaCyte Biotech make?

PharmaCyte Biotech has a market capitalization of $53.65 million.

How many employees does PharmaCyte Biotech have?

PharmaCyte Biotech employs 4 workers across the globe.

What is PharmaCyte Biotech's official website?

The official website for PharmaCyte Biotech is www.pharmacyte.com.

Where are PharmaCyte Biotech's headquarters?

PharmaCyte Biotech is headquartered at 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653.

How can I contact PharmaCyte Biotech?

PharmaCyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The company can be reached via phone at (917) 595-2850, via email at [email protected], or via fax at 917-595-2851.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.